trkain1

TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) [IC50: 99 nM in a cell-based assay] with analgesic activity.

ITK/TRKA-IN-1 is a chemical compound that functions as a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA). With an IC50 value of 1.0 nM, it effectively inhibits ITK activity and demonstrates a remarkable 96% inhibition of TRKA.

TrkA-IN-10 (PI-15R) is a TrkA inhibitor with IC50 values of 17 nM, 8 nM, and 5 nM for TrkA, TrkB, and TrkC, respectively. It is utilized in cancer research.

RET/TRKA-IN-1 (Compound 13) is a dual inhibitor targeting RET with an IC50 of 0.375 µM and TRKA. It reduces cell viability of LC-2 and KM12, with GI50 values of 0.72 and 0.25 µM respectively. RET/TRKA-IN-1 also induces cell cycle arrest at the G1 phase.

hTrkA-IN-1 is a potent and orally active inhibitor of TrkA kinase with an IC 50 of 1.3 nM, compound 2.hTrkA-IN-1 can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al.

FLT3/TrKA-IN-1 is a potent dual kinase inhibitor that targets FLT3 (IC50: 43.8 nM), FLT3-ITD (IC50: 97.2 nM), FLT3-TKD (IC50: 92.5 nM), and TrKA (IC50: 23.6 nM). FLT3/TrKA-IN-1 shows potential for acute myeloid leukaemia (AML) studies.